Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1973 7
1974 9
1975 7
1976 28
1977 26
1978 33
1979 26
1980 29
1981 34
1982 33
1983 50
1984 39
1985 55
1986 52
1987 47
1988 49
1989 52
1990 50
1991 43
1992 50
1993 43
1994 62
1995 53
1996 56
1997 66
1998 43
1999 70
2000 60
2001 43
2002 55
2003 54
2004 59
2005 64
2006 64
2007 77
2008 85
2009 79
2010 85
2011 93
2012 84
2013 104
2014 95
2015 104
2016 85
2017 99
2018 86
2019 82
2020 77
2021 43
Text availability
Article attribute
Article type
Publication date

Search Results

2,567 results
Results by year
Filters applied: . Clear all
Page 1
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N. Tanum L, et al. JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205. doi: 10.1001/jamapsychiatry.2017.3206. JAMA Psychiatry. 2017. PMID: 29049469 Free PMC article. Clinical Trial.
INTERVENTIONS: Randomization to either daily oral flexible dose buprenorphine-naloxone, 4 to 24 mg/d, or extended-release naltrexone hydrochloride, 380 mg, administered intramuscularly every fourth week for 12 weeks. ...Eighty individuals were randomized to extended-releas …
INTERVENTIONS: Randomization to either daily oral flexible dose buprenorphine-naloxone, 4 to 24 mg/d, or extended-release naltrexone …
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
Murphy SM, McCollister KE, Leff JA, Yang X, Jeng PJ, Lee JD, Nunes EV, Novo P, Rotrosen J, Schackman BR. Murphy SM, et al. Ann Intern Med. 2019 Jan 15;170(2):90-98. doi: 10.7326/M18-0227. Epub 2018 Dec 18. Ann Intern Med. 2019. PMID: 30557443 Free PMC article. Clinical Trial.
BACKGROUND: Not enough evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating opioid use disorder. ...PERSPECTIVE: Health care sector and societal. INTERVENTIONS: Buprenorphine-naloxone and extended-release naltrexone. OUTCOM …
BACKGROUND: Not enough evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating opioid use dis …
Low-dose oral naloxone reverses opioid-induced constipation and analgesia.
Liu M, Wittbrodt E. Liu M, et al. J Pain Symptom Manage. 2002 Jan;23(1):48-53. doi: 10.1016/s0885-3924(01)00369-4. J Pain Symptom Manage. 2002. PMID: 11779668 Free article. Clinical Trial.
Patients were given 4 mg or 2 mg of oral naloxone, or placebo, three times daily. Stool frequency and symptoms related to constipation were recorded daily. ...Patients using high doses of opioids appear to be the most vulnerable to the analgesic effect of oral naloxone
Patients were given 4 mg or 2 mg of oral naloxone, or placebo, three times daily. Stool frequency and symptoms related to constipatio …
A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, et al. Bracken MB, et al. N Engl J Med. 1990 May 17;322(20):1405-11. doi: 10.1056/NEJM199005173222001. N Engl J Med. 1990. PMID: 2278545 Free article. Clinical Trial.
Studies in animals indicate that methylprednisolone and naloxone are both potentially beneficial in acute spinal-cord injury, but whether any treatment is clinically effective remains uncertain. We evaluated the efficacy and safety of methylprednisolone and naloxone
Studies in animals indicate that methylprednisolone and naloxone are both potentially beneficial in acute spinal-cord injury, but whe …
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W. Hser YI, et al. Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9. Addiction. 2014. PMID: 23961726 Free PMC article. Clinical Trial.
AIMS: To examine patient and medication characteristics associated with retention and continued illicit opioid use in methadone (MET) versus buprenorphine/naloxone (BUP) treatment for opioid dependence. DESIGN, SETTINGS AND PARTICIPANTS: This secondary analysis included 12 …
AIMS: To examine patient and medication characteristics associated with retention and continued illicit opioid use in methadone (MET) versus …
[Randomized double-blind clinical trial of moderate dosage naloxone in acute moderate and severe traumatic brain injury].
Chen B, Liu YS. Chen B, et al. Hunan Yi Ke Da Xue Xue Bao. 2002 Feb 28;27(1):58-60. Hunan Yi Ke Da Xue Xue Bao. 2002. PMID: 12575238 Clinical Trial. Chinese.
Naloxone or saline placebo was intravenously given for 10 days. We followed up for at least 1 month. ...The mortalities of the naloxone group and the saline group were 0 and 5% respectively. After the one-month follow-up, Glasgow outcome scale and verbal function in
Naloxone or saline placebo was intravenously given for 10 days. We followed up for at least 1 month. ...The mortalities of the nal
Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study.
Weisshaar S, Brandt L, Litschauer B, Sheik-Rezaei S, Moser L, Nirnberger G, Kühberger E, Bauer U, Firbas C, Gouya G, Wolzt M, Fischer G. Weisshaar S, et al. Br J Clin Pharmacol. 2020 Aug;86(8):1610-1619. doi: 10.1111/bcp.14271. Epub 2020 Mar 20. Br J Clin Pharmacol. 2020. PMID: 32145041 Free PMC article. Clinical Trial.
For statistical analysis, the area under the curve between baseline and 20 minutes after drug administration of the outcome variables was calculated. RESULTS: Intravenous morphine-naloxone caused rapid withdrawal symptoms. Coadministration of naloxone dose-dependent …
For statistical analysis, the area under the curve between baseline and 20 minutes after drug administration of the outcome variables was ca …
A randomized clinical trial of the effects of ultra-low-dose naloxone infusion on postoperative opioid requirements and recovery.
Xiao Y, Wu L, Zhou Q, Xiong W, Duan X, Huang X. Xiao Y, et al. Acta Anaesthesiol Scand. 2015 Oct;59(9):1194-203. doi: 10.1111/aas.12560. Epub 2015 Jun 4. Acta Anaesthesiol Scand. 2015. PMID: 26041316 Clinical Trial.
We hypothesized that naloxone prevents the acute opioid tolerance produced by a large dose of remifentanil, and reduces the incidence of opioid-induced side effects. ...RESULTS: Cumulative morphine consumption at 24 h after surgery was higher in the large-dose remifentanil …
We hypothesized that naloxone prevents the acute opioid tolerance produced by a large dose of remifentanil, and reduces the incidence …
Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids.
Winhusen T, Wilder C, Lyons MS, Theobald J, Kropp F, Lewis D. Winhusen T, et al. Drug Alcohol Depend. 2020 Nov 1;216:108265. doi: 10.1016/j.drugalcdep.2020.108265. Epub 2020 Aug 31. Drug Alcohol Depend. 2020. PMID: 32919098 Free PMC article. Clinical Trial.
BACKGROUND: Opioid overdose prevention education and naloxone distribution (OEND) programs include information on general risk factors, overdose recognition, and naloxone utilization. ...Participants completed in-person visits at 3 (n = 66), 6 (n = 58), and 12 (n = …
BACKGROUND: Opioid overdose prevention education and naloxone distribution (OEND) programs include information on general risk factor …
Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.
Skulberg AK, Tylleskar I, Nilsen T, Skarra S, Salvesen Ø, Sand T, Loftsson T, Dale O. Skulberg AK, et al. Eur J Clin Pharmacol. 2018 Jul;74(7):873-883. doi: 10.1007/s00228-018-2443-3. Epub 2018 Mar 22. Eur J Clin Pharmacol. 2018. PMID: 29568976 Clinical Trial.
PURPOSE: This study aimed to develop a model for pharmacodynamic and pharmacokinetic studies of naloxone antagonism under steady-state opioid agonism and to compare a high-concentration/low-volume intranasal naloxone formulation 8 mg/ml to intramuscular 0.8 mg. ...I …
PURPOSE: This study aimed to develop a model for pharmacodynamic and pharmacokinetic studies of naloxone antagonism under steady-stat …
2,567 results